pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-1231 |
Genomic Coordinates | chr1: 201808611 - 201808702 |
Synonyms | MIRN1231, hsa-mir-1231, MIR1231 |
Description | Homo sapiens miR-1231 stem-loop |
Comment | None |
RNA Secondary Structure | |
Associated Diseases |
Mature miRNA Information | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mature miRNA | hsa-miR-1231 | |||||||||||||||
Sequence | 5| GUGUCUGGGCGGACAGCUGC |24 | |||||||||||||||
Evidence | Experimental | |||||||||||||||
Experiments | Cloned | DRVs in miRNA |
|
|||||||||||||
SNPs in miRNA |
|
|||||||||||||||
Putative Targets |
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | SOX5 | ||||||||||||||||||||
Synonyms | L-SOX5, L-SOX5B, L-SOX5F, LAMSHF | ||||||||||||||||||||
Description | SRY-box 5 | ||||||||||||||||||||
Transcript | NM_006940 | ||||||||||||||||||||
Other Transcripts | NM_152989 , NM_178010 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on SOX5 | |||||||||||||||||||||
3'UTR of SOX5 (miRNA target sites are highlighted) |
>SOX5|NM_006940|3'UTR 1 TAAGGGTCAAAAGATTGTTGTGACCTTAGGACTTAAAGAAGCCCTAACTGGTTCATCCTTACCAGTGGCCAAGCACATTA 81 ACTTTCTCATACACTGACTGTTACTTTAACTGTTAGTCTTAAATAGTTGGGACATCAGCTGACTAATAGACCTCAGCCTC 161 AAAAGGCTTGGAAAGAAAAAACAAATACAACAAGCAAACAACAATATCAACAACAAGAGATTGAAATAAGCTATGGGTAA 241 AATAATGCCAGTAATTCAGCTGCTACATCCAAGCACTGAAGTCTTACCCGTCAACTTTTTTTTTTTTTTAAATAAACTTT 321 ATGGCTGTTTGTTCTACAATGTTCTAGAAATTCTCACTCAGGTACACAGTGCCAACAAGTGGCTTGTGAATGTGTTTTGT 401 TGTTTTGTGCTACAATTTTTAAAAAGAAAAAAGTTTTGTTTTGTTTTTTGGGGTTTCTGGGTTTTTTCCTTTTCTTTTTC 481 TTTCCTTTCATTTTTTTTCTTTGTAATGCACCTGACAGAAAAAAAAGAAAAATGAATTTCTCTTTACTTCTCTCCACCTT 561 CTCCATCTCTCTACTTTAAAGATGGAAGTCTGTGCATGAGGGGAAAGAGGGAAAAAGAGCCTGTTTTTAACTTCCTTGCT 641 ATCCACCACAAAATAAGCAATTATTTTCTTTAGAGGACTTTATCTATTGCACACCACACTACATCTTTGAGCAAGTGCCA 721 AATTTGTACTGAAGTGTTGACCAAGTTCATTTTTTCTCTTTACTTTTTCCTTTTCCTTCTTAAGTTAGGACAGTGTTAAA 801 TCTTAGACAATCCCTTGAAAAACCTGAAATACCAGCAGCTGGTGAGATTTGACTTTTTTTTTTAATGGAAACTGTAGGTG 881 CTGTTCTCAGGTGAAAAGAGAGAGAGAGAGAGAGACATAAGAAATTTAGAGAAAAATATTTTCTGATCTTGGATTTTTGT 961 GTGTATGTATGTATGTGATTATGGTACTAATAATAGGAATAACGTTGGACCATTGTGAGTTAAACCCACATCTGGGGATG 1041 AAATCCCACATCCTCCCAAGTGACTGGTCTAGAAATAATCTTGACCTTGACTTTGCACTTCAAATGACAACTTAACCAAG 1121 TATAGGGCTCAGAAATTATATTTTTAAATGTCTGATTATTATTGGATGGATCAGGTGGCCCTGTGTAATAGAGGTGTGCA 1201 TGTATAACATGGAAGCTACTAGCAAACTGCTCCCAGATGTCCTTTCTCCCTGGTCAGTTGGTTCCATTAACGTTTGCTAC 1281 TTAGTGATTTTTGTTTTTCCTGTTGATATTTTGAGCAAAACAATCATTGTTTTCATTGAATATATTTGGCCATTTTTTCA 1361 GACAAATAGAATTAGCTTATTTCTTCAACATTCCATCCTTTCCCGATCAGGAAATGAAACTGATGATTTTATAAGGTATT 1441 TTTCACCCCTCCATGAAGTGAGGTGGAGGCCTTTAGCATTTCAGAAGTGTGGGCCATATGTAGTTCATGCCATAAAAAGT 1521 AGGATTTAATTAAAAGTCATTGCAGCCCAATAAAATGGAGCCTGGCTGCACCCAGGGATCCTTGCCACTGCTCTTCCCTT 1601 GCTGTCAGATTAATCCACTGAAGTCCAACTTTGGTTCAAGCAGAGTATTTGCAAAGAGCAACAACTGAATGTGATGGGAC 1681 TGCTTATGTAGATTTTGCCAGCCAAATGCCAAGGCAGTTGTAGGGCCTGTACAAATAAATGCAAAATCATTTCAAGTCAA 1761 TTGCCATTATTTGTATTGAAGTATCAGATAGATAGTAAATACTGCAACTAGTAGCTTGATGTGCTATAGTTTTCACTCCA 1841 GTCATCATTTTCCTATCTCACCCCCCGAAACACCACCCTAAAGTTGGATTTTTACATATAAATAAAAAAAGAATCCCTTT 1921 TATTTTTCTCTCTCTCAGAAGACTTGCTCTGGGGTTTTGCTTGGAGGAGCTGATCATATCCTGCATGTCAGAGATTTCAT 2001 TTTGTTTGTTTTTCTGTTTGTTTGTTTTTGATGACTTTATTTACATTTGAACTGCCTCTTTTTGCTAGTGTTGTAATGAT 2081 GATGATGATAAAATAATAATAATAATAGTAATAATAATAATAATGGTCAGCTGTTCCCAGATTAGTAAGTTATGTATAAT 2161 TTATTTTATTTCTCCCTTTCTATTTTATTCTGCTCTGATTTGGAAGTGCAGCCAATAAGCTGTTAGATATTTAAAACAAA 2241 TTTCCATCTCCAACTCATATATGTATGTATATGTATATATATATATACATATATATACACACATATACACACACACACAC 2321 ACATTTACCCACAATTTTACTTCTCTTTCCGTAAGTTTTCTCTTTTTTAAGAATTTTGGCCCCAACAATATCAGTTCTGA 2401 TGTTTAAAACAAAGGAGTGAATTAATAGGAGGGTCGTGTTCAATCTTAATTAACTTATGCTCTCATCACTCATTTTAGTT 2481 ATTTAATTGCCACAGTCATCTAGAGCCAATTTTTTTTTGTTTTTGTTTGTTTTGTTTTTAAGCACTCTGGATAAGGAAAA 2561 AATAGACACTTGTTTTTATATCATTTTTATGTACAATGTGAAAACAGATTTTTAAAAAATTTGTTCTCTGTCTTTGTTAA 2641 CAAATTCCTTCCGATTTATGTGGGTTCACCTCTCACGTTTGCTGGATACTTACTTTACACCATGTTATGAAAGATGCTTT 2721 GTTTTCATTTCATGAGTTTGGGCTACAAGAATACTTTGTTTTAGCTCCAGGTAGATGCCATTGAAGGCATTCATGGCTGA 2801 AATCAATTCTAACACACTTACCGATGAATTGACAACACTTTGGTGTTTGGTCTTTTTTTTGTTATATTTTGTTTTATTTG 2881 AAGGGGAAAACAAAATTGTTAATGGTGACTTTTAACTGCTGAAATTCAAAATTTGATTTTAGTTAGGTTTATGTCCGAGA 2961 CTAAACTGTGCATGAACCGAAACAAAAAGCAAGTTCATACCGCTGCATTCTGTTCTCTTGTTCTGACGGTTAATTCACTG 3041 GACATCAAATTTTCTTTGCCCTAGTTTTCCCCAAAAGAAAACAAAAGCAAAAATAGTTATATTAATGTTGAAAGTGCTTT 3121 GAAGTCACTTGATAAAAGGTGCTATGAATAGCAACTTACTGTGTTACTACATTGCCTTTTTGGCATTGGTTGATTTATAA 3201 TTTTGGTAAAGGATCCTAAAACCCTGTATTCTTTTTCTGTGCCCCATAATGACCAAAAAAGATAAAGAAAATGAGAGTAA 3281 GATCAAAAGATCAAACTAAAACATAAACAGTCTCCTTCCTGTCTGCTTTCTTACCTATCTGTTCACACTTTATCTCTTTC 3361 CCTTTCTCTCTCTCTCTCACATGCGCGCGCGCGCGCGCGCACACACACACACACACACACTTGCCCCAACACTGAGAAAT 3441 AATCTTGCCAGAATTCTGGTTTTTATAGTTGTTGTAGTCCGTTTCTCTAAAAATAGTCCTGTTTTCATATGAATCTAAGA 3521 GAACATTACCGGAGAAAATAAAGTTACTCATTTATAGTTACTAATAATAAGTTAGTGATTAACTTACCACAATTGGATAA 3601 AATATAAAACTATTCTTCAGCACATTTATACCTAAATTAGTGAAGTCCATTTGTGAAGTTCATTTGGCATCTGCAGTTAA 3681 GAGTTAACCATGTATAAAATCCCTCCCAAAGAACATAATCATCGTTAGAACCAAATCCTCTTATAAAGAACAAATATAAA 3761 AAAGTTTTCTGTGGTGAAGCTATTTTATAGATTTGATTTCCGGAGTAGAATTTTACCTTAATTCACTTAAAGAAAATTAA 3841 CCATTTTTTGGTCCAACTTCAGATATTTTCTTAATCCAGAAGCTGTGACTGTTCCCAGAAGAAACCTCTTATATCACATT 3921 TAAAACATAAAAAATAATTACACTTTCACTCATTCTAATGGGTAAATTGTTGAATTGTAATAAACAACTGTATATTTACA 4001 AACAGGTTTATAAGGTATTTGTCTATCAAATTAATAATAAAATAAAACTTACGGGGTCTGCAAGGAAAACTATGAAGGCC 4081 ACTTAAAGTGGTTCAGGTATCCCTTTGTCTTGTAGGGCATAGCTGTTGGTTTAGCCAGGCTTTTACAGTATTTAATTTTA 4161 AAGTATCCTATAACTATCAACTTCCCAGGTTGAAGACGATGTGTTGAGTTTCCTACTGATTGATTGATTCCTGTCCTCCC 4241 CAGTGTTTCCGTCACTGGTTCACTAAAACAGTATTTATATAGCTCCACTGGCTCTAAAGCTCTTAGTCCTTCTAATATTT 4321 TGGATTTTACAAGTAAAAATGGAAAAAAAATAGAAAAGAGACAATCAAATGCCTGGAGCTTAAAACAAAGTATGTGCAAC 4401 CTACCATCTCACTTGAAATTTAATAAAATAATAAGTAATTATGTAAATATAACATAGAGTTATAGATTTATATTTTGTTC 4481 ATAACACATAGTGTAATATAAGTTGTATATTTTCATGTTTTTGGTTTTATGTTATCATTCATGCCACAATAAAAATAAAA 4561 CAGGAGTTTATGTGCTCTTAAAAAAAAGATGTGGGTTGCCACCAACCTGTTTTTCGTTTTTGTTTTTTGTTTATTTTATT 4641 TTATTTTTTTGCATTCTCCTTTTTCAGTATTACTGCCATGCAAGGCACCAATAAAAACAGCAAATGTGTTCTTTAAAAAA 4721 AAAAAAAAAAAA Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
||||||||||||||||||||
DRVs in gene 3'UTRs | |||||||||||||||||||||
SNPs in gene 3'UTRs |
Experimental Support 1 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Conditions | BC-3 |
Location of target site | 3'UTR |
Tools used in this research | TargetScan , miRTarCLIP , Piranha |
Original Description (Extracted from the article) |
...
PAR-CLIP data was present in GSM796040. RNA binding protein: AGO2. Condition:4-Thiouridine
... - Gottwein E; Corcoran DL; Mukherjee N; et al., 2011, Cell host & microbe. |
Article |
- Gottwein E; Corcoran DL; Mukherjee N; et al. - Cell host & microbe, 2011
Primary effusion lymphoma (PEL) is caused by Kaposi's sarcoma-associated herpesvirus (KSHV) and frequently also harbors Epstein-Barr virus (EBV). The expression of KSHV- and EBV-encoded microRNAs (miRNAs) in PELs suggests a role for these miRNAs in latency and lymphomagenesis. Using PAR-CLIP, a technology which allows the direct and transcriptome-wide identification of miRNA targets, we delineate the target sites for all viral and cellular miRNAs expressed in PEL cell lines. The resulting data set revealed that KSHV miRNAs directly target more than 2000 cellular mRNAs, including many involved in pathways relevant to KSHV pathogenesis. Moreover, 58% of these mRNAs are also targeted by EBV miRNAs, via distinct binding sites. In addition to a known viral analog of cellular miR-155, we show that KSHV encodes a viral miRNA that mimics cellular miR-142-3p function. In summary, this study identifies an extensive list of KSHV miRNA targets, which are likely to influence viral replication and pathogenesis.
LinkOut: [PMID: 22100165]
|
CLIP-seq Support 1 for dataset GSM796040 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | BC-3 / 4-Thiouridine |
Location of target site | ENST00000546136.1 | 3UTR | UUGGCCAUUUUUUCAG |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 22100165 / GSE32109 |
CLIP-seq Viewer | Link |
MiRNA-Target Expression Profile | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | |||||||
---|---|---|---|---|---|---|---|
|
37 hsa-miR-1231 Target Genes:
Functional analysis:
ID | Target | Description | Validation methods | |||||||||
Strong evidence | Less strong evidence | |||||||||||
MIRT075228 | PHF13 | PHD finger protein 13 | 2 | 6 | ||||||||
MIRT266936 | HDGF | heparin binding growth factor | 2 | 6 | ||||||||
MIRT441394 | SOX5 | SRY-box 5 | 2 | 2 | ||||||||
MIRT446329 | ATP5C1 | ATP synthase, H+ transporting, mitochondrial F1 complex, gamma polypeptide 1 | 2 | 2 | ||||||||
MIRT446438 | THYN1 | thymocyte nuclear protein 1 | 2 | 2 | ||||||||
MIRT482781 | STIM1 | stromal interaction molecule 1 | 2 | 2 | ||||||||
MIRT497714 | CYP1A1 | cytochrome P450 family 1 subfamily A member 1 | 2 | 2 | ||||||||
MIRT500907 | STARD13 | StAR related lipid transfer domain containing 13 | 2 | 2 | ||||||||
MIRT503251 | KIF18B | kinesin family member 18B | 2 | 2 | ||||||||
MIRT504750 | TEP1 | telomerase associated protein 1 | 2 | 4 | ||||||||
MIRT512158 | CD164 | CD164 molecule | 2 | 6 | ||||||||
MIRT518043 | LSM3 | LSM3 homolog, U6 small nuclear RNA and mRNA degradation associated | 2 | 4 | ||||||||
MIRT526038 | GMDS | GDP-mannose 4,6-dehydratase | 2 | 2 | ||||||||
MIRT529828 | ARGFX | arginine-fifty homeobox | 2 | 2 | ||||||||
MIRT531808 | POLD3 | DNA polymerase delta 3, accessory subunit | 2 | 2 | ||||||||
MIRT533139 | WNT10A | Wnt family member 10A | 2 | 2 | ||||||||
MIRT538612 | CCT5 | chaperonin containing TCP1 subunit 5 | 2 | 4 | ||||||||
MIRT555617 | PHLPP2 | PH domain and leucine rich repeat protein phosphatase 2 | 2 | 2 | ||||||||
MIRT561705 | PTP4A1 | protein tyrosine phosphatase type IVA, member 1 | 2 | 2 | ||||||||
MIRT562301 | GINM1 | glycoprotein integral membrane 1 | 2 | 2 | ||||||||
MIRT566732 | MSH6 | mutS homolog 6 | 2 | 2 | ||||||||
MIRT569369 | IMPG1 | interphotoreceptor matrix proteoglycan 1 | 2 | 2 | ||||||||
MIRT572314 | HSPB6 | heat shock protein family B (small) member 6 | 2 | 2 | ||||||||
MIRT574602 | LZIC | leucine zipper and CTNNBIP1 domain containing | 2 | 2 | ||||||||
MIRT612023 | FOXF2 | forkhead box F2 | 2 | 2 | ||||||||
MIRT616950 | MAPKAPK2 | mitogen-activated protein kinase-activated protein kinase 2 | 2 | 2 | ||||||||
MIRT624175 | DERL2 | derlin 2 | 2 | 2 | ||||||||
MIRT647634 | FAIM2 | Fas apoptotic inhibitory molecule 2 | 2 | 2 | ||||||||
MIRT659393 | CORO2A | coronin 2A | 2 | 2 | ||||||||
MIRT659955 | CXCL10 | C-X-C motif chemokine ligand 10 | 2 | 2 | ||||||||
MIRT684001 | FOLR1 | folate receptor 1 | 2 | 2 | ||||||||
MIRT688143 | GABPB1 | GA binding protein transcription factor beta subunit 1 | 2 | 2 | ||||||||
MIRT688609 | CYBRD1 | cytochrome b reductase 1 | 2 | 2 | ||||||||
MIRT693583 | SLC39A1 | solute carrier family 39 member 1 | 2 | 2 | ||||||||
MIRT699922 | RUFY2 | RUN and FYVE domain containing 2 | 2 | 2 | ||||||||
MIRT712961 | PET117 | PET117 homolog | 2 | 2 | ||||||||
MIRT723950 | TMEM184A | transmembrane protein 184A | 2 | 2 |
miRNA-Drug Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
miRNA-Drug Resistance Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|